One possible mode by which IL-6 may influence progression of prostate cancer to the hormone-refractory state is by activating the IL-6 receptor/JAK1/STAT3 pathway, resulting in differentiation and inhibition of apoptosis (Spiotto and Chung, 2000a; Smith et al, 2001). This evidence concerns the gene IL6 and prostate carcinoma.